Sapu BioScience has been developing TGFB2-targeted antisense therapeutics, establishing one of the deepest proprietary knowledge bases around this pathway in oncology. That work has generated a broad ...

Three of the biotech industry’s trusted advisory firms: KreaMedica, Venture Valuation, and Lacerta Bio, today announced the release of The First-Time Biotech CEO Playbook, a practical guide designed ...

Notably, the company completed its End-of-Phase 2 (EOP2) interactions with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA).

Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole : IVA, ISIN : FR0013233012) et sur le Nasdaq Global Market aux États-Unis (symbole : IVA).

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has ...

Proposal No. 6: The Company’s name be changed from “Hong Kong Pharma Digital Technology Holdings Limited” to “Cellyan Biotechnology Co., Ltd” and the Company’s foreign name be changed from ...

Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, with their partner Breakthrough Genomics, a leader in the clinical analysis of ...

Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to ...

The Rising Stars program is a cornerstone BioNTX platform designed to elevate emerging companies by providing visibility, credibility, and direct access to investors, industry leaders, and strategic ...

Clinically validated platform delivers predictive precision, empowering clinicians with real-time visibility to reduce preventable complications and improve patient outcomes “Value-based care is under ...

The OraSure Board and management team are committed to moving the Company forward with a clear focus on shareholder value creation. We maintain open and constructive dialogue with our shareholders, ...

Attending the events surrounding the J.P. Morgan Healthcare Conference in San Francisco is a great opportunity for Cadrenal Therapeutics to engage directly with current and prospective partners and ...